BRIEF-翰森制药称奥莱泊肽注射液上市许可申请获国家药品监督管理局受理

路透中文
Jun 04
BRIEF-<a href="https://laohu8.com/S/03692">翰森制药</a>称奥莱泊肽注射液上市许可申请获国家药品监督管理局受理

路透北京6月4日 - Hansoh Pharmaceutical Group Company Ltd 3692.HK

* 本集团创新药奥莱泊肽注射液上市许可申请(NDA)获中国国家药品监督管理局(NMPA)受理,适用于肥胖或超重成人的长期体重管理

* 奥莱泊肽是一款本集团自主研发的每周一次给药胰高血糖素样肽-1(GLP-1)╱葡萄糖依赖性促胰岛素多肽(GIP)双受体激动剂(完)

公告全文,请点击此处

(发稿 刘珞焱)

((luoyan.liu@tr.com; +86 021 2083 0166;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10